Original language | English |
---|---|
Pages (from-to) | 1486-1490 |
Number of pages | 5 |
Journal | European Journal of Heart Failure |
Volume | 22 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 1 2020 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Implications of serial measurements of natriuretic peptides in heart failure : insights from BIOSTAT-CHF. / Israr, Muhammad Zubair; Salzano, Andrea; Yazaki, Yoshiyuki et al.
In: European Journal of Heart Failure, Vol. 22, No. 8, 01.08.2020, p. 1486-1490.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Implications of serial measurements of natriuretic peptides in heart failure
T2 - insights from BIOSTAT-CHF
AU - Israr, Muhammad Zubair
AU - Salzano, Andrea
AU - Yazaki, Yoshiyuki
AU - Voors, Adriaan A.
AU - Ouwerkerk, Wouter
AU - Anker, Stefan D.
AU - Cleland, John G.
AU - Dickstein, Kenneth
AU - Metra, Marco
AU - Samani, Nilesh J.
AU - Ng, Leong L.
AU - Suzuki, Toru
N1 - Funding Information: BIOSTAT‐CHF was supported by the European Commission [FP7‐242209‐BIOSTAT‐CHF; EudraCT 2010–020808‐29]. The present analysis was supported by the following funding to T.S.: the Practical Research Project for Life‐Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus from Japan Agency for Medical Research and Development (AMED) (17ek0210011h0005), the Japan Heart Foundation, the University of Tokyo, Sekisui Medical Co., the John and Lucille van Geest Foundation, the National Institute for Health Research Leicester Biomedical Research Centre, the British Heart Foundation and the Medical Research Council through its partnership grant for the UK Consortium on MetAbolic Phenotyping (MAP/UK). Funding Information: Conflict of interest: A.S. receives research grant support from CardioPath, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy, UniNA and Compagnia di San Paolo in the frame of the STAR (Sostengo Territoriale alla Attività di Ricerca) programme. S.D.A. reports grants and/or committee fees from Vifor Int and Abbott Vascular, Bayer, Boehringer Ingelheim, Novartis and Servier. J.G.C. has received consulting honoraria fees and/or research grants from Johnson & Johnson, Amgen, AstraZeneca, Bayer, Bristol‐Myers Squibb, GSK, Medtronic, Myokardia, Novartis, Philips, Pharmacosmos, PharmaNord, Sanofi, Servier, Stealth Biopharmaceuticals, Torrent Pharmaceuticals and Vifor. M.M. has received grants from the European Community, and participation in advisory boards with fees from Novartis and Bayer. L.L.N. has received grants from EU FP7. All other authors have nothing to disclose. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/1
Y1 - 2020/8/1
UR - http://www.scopus.com/inward/record.url?scp=85088797162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088797162&partnerID=8YFLogxK
U2 - 10.1002/ejhf.1951
DO - 10.1002/ejhf.1951
M3 - Letter
C2 - 32666670
AN - SCOPUS:85088797162
SN - 1388-9842
VL - 22
SP - 1486
EP - 1490
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 8
ER -